Skip to content

Relmada Therapeutics, Inc.

RLMD

CIK 0001553643

← back to feed
Revenue (TTM)
$5.51K
−35.4% YoY Q1 May 2026
Net Income (TTM)
−$56.57M
+28.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.40
+45.3% YoY Q1 May 2026
Gross Margin
17.3%
Q1 May 2026
Operating Margin
-1,056,401.3%
Q1 May 2026
Net Margin
-1,026,294.6%
Q1 May 2026
Free Cash Flow (TTM)
−$62.68M
Q1 May 2026
Cash
$9.78M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
104.89M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings